The device was not returned for analysis.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.Additionally, a review of the complaint history identified no other incidents from this lot.As there was no damage noted to the device during the inspection prior to use, it is possible that the distal sheath of the delivery system was entrapped or bent in the moderately calcified anatomy such that the ratchet was unable to properly/fully engage the stent resulting in the reported deployment difficulty/activation failure; however this cannot be confirmed.The investigation determined a conclusive cause for the reported activation failure cannot be determined.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
It was reported that the procedure was to treat a lesion in the superficial femoral artery (sfa) with moderate calcification.The 5.0x100mm supera stent was used in a procedure; however, the stent was only able to be partially deployed.Therefore, the supera device was removed from the patient.There was no adverse patient effect and no clinically significant delay in the procedure.Another supera stent was used in the procedure.No additional information was provided.
|